<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>rgpv syllabus - rgpv timetable Microsoft Word - M Pharm PCI Syllabus all branches</title><meta name="author" content="HP"/><style type="text/css"> * {margin:0; padding:0; text-indent:0; }
 .s1 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s2 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 .p, p { color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; margin:0pt; }
 a { color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 li {display: block; }
 #l1 {padding-left: 0pt;counter-reset: c1 2; }
 #l1> li>*:first-child:before {counter-increment: c1; content: counter(c1, decimal)" "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l1> li:first-child>*:first-child:before {counter-increment: c1 0;  }
 #l2 {padding-left: 0pt;counter-reset: c2 1; }
 #l2> li>*:first-child:before {counter-increment: c2; content: counter(c2, decimal)". "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l2> li:first-child>*:first-child:before {counter-increment: c2 0;  }
 li {display: block; }
 #l3 {padding-left: 0pt;counter-reset: d1 2; }
 #l3> li>*:first-child:before {counter-increment: d1; content: counter(d1, decimal)" "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l3> li:first-child>*:first-child:before {counter-increment: d1 0;  }
 #l4 {padding-left: 0pt;counter-reset: d2 1; }
 #l4> li>*:first-child:before {counter-increment: d2; content: counter(d2, decimal)". "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l4> li:first-child>*:first-child:before {counter-increment: d2 0;  }
 li {display: block; }
 #l5 {padding-left: 0pt;counter-reset: e1 2; }
 #l5> li>*:first-child:before {counter-increment: e1; content: counter(e1, decimal)" "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l5> li:first-child>*:first-child:before {counter-increment: e1 0;  }
 #l6 {padding-left: 0pt;counter-reset: e2 1; }
 #l6> li>*:first-child:before {counter-increment: e2; content: counter(e2, decimal)". "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l6> li:first-child>*:first-child:before {counter-increment: e2 0;  }
 li {display: block; }
 #l7 {padding-left: 0pt;counter-reset: f1 2; }
 #l7> li>*:first-child:before {counter-increment: f1; content: counter(f1, decimal)" "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l7> li:first-child>*:first-child:before {counter-increment: f1 0;  }
 #l8 {padding-left: 0pt;counter-reset: f2 1; }
 #l8> li>*:first-child:before {counter-increment: f2; content: counter(f2, decimal)". "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l8> li:first-child>*:first-child:before {counter-increment: f2 0;  }
 li {display: block; }
 #l9 {padding-left: 0pt;counter-reset: g1 1; }
 #l9> li>*:first-child:before {counter-increment: g1; content: counter(g1, decimal)". "; color: black; font-family:"Lucida Sans Unicode", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l9> li:first-child>*:first-child:before {counter-increment: g1 0;  }
</style><!-- Basic Meta Tags -->
<meta charset="utf-8" />
<meta http-equiv="X-UA-Compatible" content="IE=edge" />
<meta name="viewport" content="width=device-width,initial-scale=1" />

<!-- Page Title and Description -->
<title>rgpv syllabus - rgpv timetable rgpv syllabus and rgpv timetable</title>
<meta name="description" content="Download and view the latest RGPV syllabus and timetable in PDF." />
<meta name="keywords" content="download, view, RGPV, syllabus, timetable, PDF" />

<!-- Robots Meta Tag -->
<meta name="robots" content="index, follow" />
<link rel="sitemap" href="/sitemap.xml" />

<!-- Twitter Meta Tags -->
<meta name="twitter:card" content="summary_large_image" />
<meta name="twitter:title" content="RGPV Syllabus and Timetable" />
<meta name="twitter:description" content="Download and view the latest RGPV syllabus and timetable in PDF." />

<!-- Open Graph Meta Tags -->
<meta property="og:locale" content="en_IN" />
<meta property="og:type" content="website" />
<meta property="og:site_name" content="RGPV Syllabus and Timetable" />
<meta property="og:title" content="RGPV Syllabus and Timetable" />
<meta property="og:description" content="Download and view the latest RGPV syllabus and timetable in PDF." />

<!-- Other Tags -->
<link rel="prefetch" />
<meta name="audience" content="all" />
<meta name="rating" content="general" />
<meta name="generator" content="site" />
<meta name="google" content="translate" />
<meta name="theme-color" content="#4DBA87" />
<meta name="geo.placename" content="India" />
<meta name="revisit-after" content="1 days" />
<meta property="fb:admins" content="100012765211323" />
<meta name="apple-mobile-web-app-capable" content="no" />

<!-- Apple Touch Icon -->
<meta name="apple-mobile-web-app-title" content="www.rgpv-syllabus-timetable.in" />
<meta name="apple-mobile-web-app-status-bar-style" content="default" />
<link rel="apple-touch-icon" href="/img/icons/apple-touch-icon-152x152.png" />

<!-- Favicon and Icons -->
<link rel="mask-icon" href="/img/icons/safari-pinned-tab.svg" color="#4DBA87" />
<link rel="icon" type="image/png" sizes="32x32" href="/img/icons/favicon-32x32.png" />
<link rel="icon" type="image/png" sizes="16x16" href="/img/icons/favicon-16x16.png" />
<meta name="msapplication-TileImage" content="/img/icons/msapplication-icon-144x144.png" />

<!-- Search Engine Tags -->
<meta name="search engines" content="Aeiwi, Alexa, AllTheWeb, AltaVista, AOL Netfind, Anzwers, Canada, DirectHit, EuroSeek, Excite, Overture, Go, Google, HotBot, InfoMak, Kanoodle, Lycos, MasterSite, National Directory, Northern Light, SearchIt, SimpleSearch, WebsMostLinked, WebTop, What-U-Seek, AOL, Yahoo, WebCrawler, Infoseek, Excite, Magellan, LookSmart, CNET, Googlebot" />

<!-- Pingback and OpenID -->
<link rel="pingback" href="https://www.rgpv-syllabus-timetable.in/" />
<link rel="openid.delegate" href="https://www.rgpv-syllabus-timetable.in/" />

<!-- Content Type -->
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
<body><div style="display:flex;justify-content:flex-end;"><a href="#" target="_blank" download="" id="pdf-download-link"><button type="button" style="cursor:pointer;-webkit-appearance:button;color:#fff;background-color:#007bff;border-color:#007bff;display:inline-block;font-weight:400;text-align:center;white-space:nowrap;vertical-align:middle;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;border:1px solid transparent;padding:0.375rem 0.75rem;font-size:1rem;line-height:1.5;border-radius:0.25rem;transition:color .15s ease-in-out,background-color .15s ease-in-out,border-color .15s ease-in-out,box-shadow .15s ease-in-out;text-transform:none;overflow:visible;margin:0;font-family:inherit;" download>Download PDF</button></a></div><script>const a=(window.location.pathname).split("/");const filename="" + a[a.length-1] + ".pdf";document.getElementById("pdf-download-link").href=filename;</script><p class="s1" style="padding-top: 3pt;padding-left: 60pt;text-indent: 0pt;line-height: 113%;text-align: center;">PRINCIPLES OF QUALITY USE OF MEDICINES (MPP 201T)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">Scope:</p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 86%;text-align: justify;">This course is designed to impart basic knowledge and skills that are required to practice quality use of medicines (QUM) in different healthcare settings and also to promote quality use of medicines, in clinical practice, through evidence-based medicine approach.</p><p class="s2" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Objectives:</p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Upon completion of this course it is expected that students shall be able to:</p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;">  <span class="p">Understand the principles of quality use of medicines</span></p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 13pt;text-align: left;">  <span class="p">Know the benefits and risks associated with use of medicines</span></p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 13pt;text-align: left;">  <span class="p">Understand regulatory aspects of quality use of medicines</span></p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;">  <span class="p">Identify and resolve medication related problems</span></p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 13pt;text-align: left;">  <span class="p">Promote quality use of medicines</span></p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 13pt;text-align: left;">  <span class="p">Practice evidence-based medicines</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 14pt;text-indent: 0pt;text-align: center;">THEORY                                60 Hrs</p><p style="padding-top: 4pt;padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">1. <span class="s2">Introduction to Quality use of medicines (QUM): </span>Definition and Principles of QUM, Key partners and responsibilities of the partners, Building blocks in QMC, Evaluation process in QMC, Communication in QUM, Cost effective prescribing.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ol id="l1"><li data-list-text="2"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 13pt;text-align: left;">Concepts in QUM</p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 83%;text-align: justify;">Evidence based medicine: <span class="p">Definition, concept of evidence based medicine, Approach and practice of evidence based medicine in clinical settings</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 88%;text-align: justify;">Essential drugs: <span class="p">Definition, need, concept of essential drug, National essential drug policy and list</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 88%;text-align: justify;">Rational drug use: <span class="p">Definition, concept and need for rational drug use, Rational drug prescribing, Role of pharmacist in rational drug use.</span></p></li><li data-list-text="3"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 85%;text-align: justify;">QUM in various settings: <span class="p">Hospital settings, Ambulatory care/Residential care, Role of health care professionals in promoting the QUM, Strategies to promote the QUM, Impact of QUM on E-health, integrative medicine and multidisciplinary care. </span>QUM in special population: <span class="p">Pediatric prescribing, Geriatric prescribing, Prescribing in pregnancy and lactation, Prescribing in immune compromised and organ failure patients.</span></p><p style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p></li><li data-list-text="4"><p class="s2" style="padding-top: 3pt;padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">Regulatory aspects of QUM in India: <span class="p">Regulation including scheduling, Regulation of complementary medicines, Regulation of OTC medicines, Professional responsibility of pharmacist, Role of industry in QUM in medicine development.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="5"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">Medication errors: <span class="p">Definition, categorization and causes of medication errors, Detection and prevention of medication errors, Role of pharmacist in monitoring and management of medication errors</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: justify;">Pharmacovigilance:  <span class="p">Definition,  aims  and  need  for</span></p><p style="padding-left: 27pt;text-indent: 0pt;line-height: 86%;text-align: justify;">pharmacovigilance, Types, predisposing factors and mechanism of adverse drug reactions (ADRs), Detection, reporting and monitoring of ADRs, Causality assessment of ADRs, Management of ADRs, Role of pharmacist in pharmacovigilance.</p><p style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">REFERENCES:</p><ol id="l2"><li data-list-text="1."><p style="padding-top: 4pt;padding-left: 26pt;text-indent: -14pt;line-height: 86%;text-align: left;">A Textbook of Clinical Pharmacy Practice – Essential concepts and skills – Parthasarathi G, Karin Nyfort-Hansen and Milap Nahata</p></li><li data-list-text="2."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 11pt;text-align: left;">Andrews EB, Moore N. Mann’s Pharmacovigilance</p></li><li data-list-text="3."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 86%;text-align: left;">Dipiro JT, Talbert RL, Yee GC. Pharmacotherapy: A Pathophysiologic Approach</p></li><li data-list-text="4."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 87%;text-align: left;">Straus SE, Richardson WS, Glasziou P, Haynes RB. Evidence-Based Medicine: How to practice and teach it</p></li><li data-list-text="5."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 10pt;text-align: left;">Cohen MR. Medication Errors</p></li><li data-list-text="6."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 13pt;text-align: left;">Online:</p><p style="padding-left: 40pt;text-indent: -14pt;line-height: 88%;text-align: left;"><a href="http://medicinesaustralia.com.au/files/2012/05/MA_QUM_External_Red" style=" color: black; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt;" target="_blank">    </a>http://medicinesaustralia.com.au/files/2012/05/MA_QUM_External_Red uced.pdf</p><p style="padding-left: 26pt;text-indent: 0pt;line-height: 11pt;text-align: left;"><a href="http://curriculum.racgp.org.au/statements/quality-use-of-medicines/" style=" color: black; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt;" target="_blank">  </a><a href="http://curriculum.racgp.org.au/statements/quality-use-of-medicines/" target="_blank">http://curriculum.racgp.org.au/statements/quality-use-of-medicines/</a></p><p style="padding-left: 26pt;text-indent: 0pt;line-height: 12pt;text-align: left;"><a href="http://www.rug.nl/research/portal/files/14051541/Chapter_2.pdf" style=" color: black; font-family:&quot;Times New Roman&quot;, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt;" target="_blank">      </a><a href="http://www.rug.nl/research/portal/files/14051541/Chapter_2.pdf" target="_blank">http://www.rug.nl/research/portal/files/14051541/Chapter_2.pdf</a></p></li><li data-list-text="7."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 13pt;text-align: left;">Relevant review articles from recent medical and pharmaceutical literature.</p></li></ol></li></ol><p class="s1" style="padding-top: 3pt;padding-left: 138pt;text-indent: -45pt;line-height: 113%;text-align: left;">PHARMACOTHERAPEUTICS II (MPP 202T)</p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">Scope</p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 86%;text-align: justify;">This course aims to enable the students to understand the different treatment approaches in managing various disease conditions. Also, it imparts knowledge and skills in optimizing drug therapy of a patient by individualizing the treatment plan through evidence-based medicines.</p><p class="s2" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Objectives</p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: justify;">Upon completion of this course it is expected that students shall be able to:</p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 13pt;text-align: justify;">  <span class="p">Describe and explain the rationale for drug therapy</span></p><p class="s2" style="padding-top: 1pt;padding-left: 41pt;text-indent: -18pt;line-height: 86%;text-align: justify;"> <span class="p">Summarize the therapeutic approach for management of various disease conditions including reference to the latest available evidence</span></p><p class="s2" style="padding-left: 41pt;text-indent: -18pt;line-height: 89%;text-align: justify;"> <span class="p">Discuss the clinical controversies in drug therapy and evidence based medicine</span></p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">  <span class="p">Prepare individualized therapeutic plans based on diagnosis</span></p><p class="s2" style="padding-top: 1pt;padding-left: 41pt;text-indent: -18pt;line-height: 86%;text-align: justify;"> <span class="p">Identify the patient specific parameters relevant in initiating drug therapy, and monitoring therapy (including alternatives, time- course of clinical and laboratory indices of therapeutic response and adverse effect/s)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">THEORY                                60 Hrs</p><p style="padding-top: 3pt;padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">1. <span class="s2">Nervous system: </span>Epilepsy,  Parkinson&#39;s  disease,  Stroke, Headache, Alzheimer’s disease, Neuralgias and Pain pathways and Pain management.</p><ol id="l3"><li data-list-text="2"><p class="s2" style="padding-top: 1pt;padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: left;">Psychiatric disorders: <span class="p">Schizophrenia, Depression, Anxiety disorders, Sleep disorders, Drug induced psychiatric disorders </span>Renal system: <span class="p">Acute renal failure, Chronic renal failure, Renal dialysis, Drug induced renal disease</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="3"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">Infectious diseases: <span class="p">General guidelines for the rational use of antibiotics and surgical prophylaxis, Urinary tract infections, Respiratory tract infections, Gastroenteritis, Tuberculosis, Malaria, Bacterial endocarditis, Septicemia.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="4"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 87%;text-align: justify;">Infectious diseases: <span class="p">Meningitis, HIV and opportunistic infections, Rheumatic fever, Dengue fever, H1N1, Helmenthiasis, Fungal infections</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Gynecological   disorders:   <span class="p">Dysmenorrhea,  Hormone</span></p><p style="padding-left: 27pt;text-indent: 0pt;line-height: 13pt;text-align: left;">replacement therapy.</p><p style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p></li><li data-list-text="5"><p class="s2" style="padding-top: 3pt;padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">Oncology: <span class="p">General principles of cancer chemotherapy, pharmacotherapy of breast cancer, lung cancer, head &amp; neck cancer, hematological malignancies, Management of nausea and vomiting, Palliative care</span></p><p style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">REFERENCES</p><ol id="l4"><li data-list-text="1."><p style="padding-top: 6pt;padding-left: 26pt;text-indent: -14pt;line-height: 74%;text-align: left;">Roger and Walker. Clinical Pharmacy and Therapeutics - Churchill Livingstone publication.</p></li><li data-list-text="2."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 87%;text-align: left;">Joseph T. Dipiro et al. Pharmacotherapy: A Pathophysiologic Approach- Appleton &amp; Lange</p></li><li data-list-text="3."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 11pt;text-align: left;">Robins SL. Pathologic basis of disease -W.B. Saunders publication</p></li><li data-list-text="4."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 86%;text-align: left;">Eric T. Herfindal. Clinical Pharmacy and Therapeutics- Williams and Wilkins Publication</p></li><li data-list-text="5."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 86%;text-align: left;">Lloyd Young and Koda-Kimble MA Applied Therapeutics: The clinical Use of Drugs- Lippincott Williams and Wilkins</p></li><li data-list-text="6."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 87%;text-align: left;">Chisholm- Burns Wells Schwinghammer Malone and Joseph P Dipiro. Pharmacotherapy Principles and practice-– McGraw Hill Publication</p></li><li data-list-text="7."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 87%;text-align: left;">Carol Mattson Porth. Principles of Pathophysiology- Lippincott Williams and Wilkins</p></li><li data-list-text="8."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 11pt;text-align: left;">Harrison&#39;s. Principles of Internal Medicine - McGraw Hill</p></li><li data-list-text="9."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 13pt;text-align: left;">Relevant review articles from recent medical and pharmaceutical literature</p></li></ol></li></ol><p class="s1" style="padding-top: 3pt;padding-left: 14pt;text-indent: 0pt;line-height: 113%;text-align: center;">CLINICAL PHARMACOKINETICS AND THERAPEUTIC DRUG MONITORING</p><p class="s1" style="padding-left: 60pt;text-indent: 0pt;text-align: center;">(MPP 203T)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">Scope</p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 86%;text-align: justify;">This course is designed to enable students to understand the basics principles and applications of pharmacokinetics in designing the individualized dosage regimen, to interpret the plasma drug concentration profile in altered pharmacokinetics, drug interactions and in therapeutic drug monitoring processes to optimize the drug dosage regimen. Also, it enables students to understand the basic concepts of pharmacogenetics, pharmacometrics for modeling and simulation of pharmacokinetic data.</p><p class="s2" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Objectives</p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Upon completion of this course it is expected that students shall be able to:</p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 13pt;text-align: left;">  <span class="p">Design the drug dosage regimen for individual patients</span></p><p class="s2" style="padding-top: 1pt;padding-left: 41pt;text-indent: -18pt;line-height: 86%;text-align: left;">  <span class="p">Interpret and correlate the plasma drug concentrations with patients&#39; therapeutic outcomes</span></p><p class="s2" style="padding-left: 41pt;text-indent: -18pt;line-height: 88%;text-align: left;">  <span class="p">Recommend dosage adjustment for patients with renal/ hepatic impairment</span></p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 10pt;text-align: left;">  <span class="p">Recommend dosage adjustment for paediatrics and geriatrics</span></p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 13pt;text-align: left;">  <span class="p">Manage pharmacokinetic drug interactions</span></p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 13pt;text-align: left;">  <span class="p">Apply pharmacokinetic parameters in clinical settings</span></p><p class="s2" style="padding-top: 1pt;padding-left: 41pt;text-indent: -18pt;line-height: 86%;text-align: left;">  <span class="p">Interpret the impact of genetic polymorphisms of individuals on pharmacokinetics and or pharmacodynamics of drugs</span></p><p class="s2" style="padding-left: 41pt;text-indent: -18pt;line-height: 88%;text-align: left;">  <span class="p">Do pharmacokinetic modeling for the given data using the principles of pharmacometrics</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 14pt;text-indent: 0pt;text-align: center;">THEORY                                60 Hrs</p><p style="padding-top: 4pt;padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">1.  <span class="s2">Introduction to Clinical pharmacokinetics: </span>Compartmental and Non compartmental models, Renal and non-renal clearance, Organ extraction and models of hepatic clearance, Estimation and determinants of bioavailability, Multiple dosing, Calculation of loading and maintenance doses</p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Designing of dosage regimens: <span class="p">Determination of dose and</span></p><p style="padding-left: 27pt;text-indent: 0pt;line-height: 85%;text-align: left;">dosing intervals, Conversion from intravenous to oral dosing, Nomograms and Tabulations in designing dosage regimen.</p><p style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><ol id="l5"><li data-list-text="2"><p class="s2" style="padding-top: 3pt;padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">Pharmacokinetics of Drug Interaction: <span class="p">Pharmacokinetic drug interactions</span>, <span class="p">Inhibition and Induction of Drug metabolism</span>, <span class="p">Inhibition of Biliary Excretion</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: justify;">Pharmacogenetics: <span class="p">Genetic polymorphism in Drug metabolism:</span></p><p style="padding-left: 27pt;text-indent: 0pt;line-height: 86%;text-align: justify;">Cytochrome P-450 Isoenzymes, Genetic Polymorphism in Drug Transport  and  Drug  Targets,  Pharmacogenetics  and Pharmacokinetic / Pharmacodynamic considerations</p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 85%;text-align: justify;">Introduction to Pharmacometrics: <span class="p">Introduction to Bayesian Theory, Adaptive method or Dosing with feedback, Analysis of Population pharmacokinetic Data.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="3"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">Non Linier Mixed Effects Modelling: <span class="p">The Structural or Base Model, Modeling Random Effects, Modeling Covariate Relationships, Mixture Model, Estimation Methods, Model Building Techniques, Covariate Screening Methods, Testing the model assumptions, Precision of the parameter estimates and confidence intervals, Model misspecification and violation of the model assumptions, Model Validation, Simulation of dosing regimens and dosing recommendations, Pharmacometrics software.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="4"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">Altered Pharmacokinetics: <span class="p">Drug dosing in the elderly, Drug dosing in the paediatrics, Drug dosing in the obese patients, Drug dosing in the pregnancy and lactation</span>, <span class="p">Drug dosing in the renal failure and extracorporeal removal of drugs, Drug dosing in the in hepatic failure.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="5"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: left;">Therapeutic Drug monitoring: <span class="p">Introduction, Individualization of drug dosage regimen (Variability – Genetic, age, weight, disease and Interacting drugs), Indications for TDM, Protocol for TDM, Pharmacokinetic/Pharmacodynamic Correlation in drug therapy, TDM of drugs used in the following conditions: Cardiovascular disease: Digoxin, Lidocaine, Amiodarone</span>; <span class="p">Seizure disorders: Phenytoin, Carbamazepine, Sodium Valproate</span>;  <span class="p">Psychiatric conditions:  Lithium,  Fluoxetine,  Amitriptyline;  Organ transplantations: Cyclosporine</span>; <span class="p">Cytotoxic Agents: Methotrexate, 5- FU,   Cisplatin;  Antibiotics:  Vancomycin,  Gentamicin, Meropenem.</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p class="s2" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">REFERENCES</p><ol id="l6"><li data-list-text="1."><p style="padding-top: 6pt;padding-left: 26pt;text-indent: -14pt;line-height: 73%;text-align: justify;">Leon Shargel, Susanna Wu-Pong, Andrew Yu. Applied Biopharmaceutics &amp; Pharmacokinetics. New York: Mc Graw Hill.</p></li><li data-list-text="2."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 86%;text-align: justify;">Peter L. Bonate. Pharmacokinetic - Pharmacodynamic Modeling and Simulation. Springer Publications.</p></li><li data-list-text="3."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 86%;text-align: justify;">Michael E. Burton, Leslie M. Shaw, Jerome J. Schentag, William E.Evans. Applied Pharmacokinetics &amp; Pharmacodynamics: Principles of Therapeutic Drug Monitoring. Iippincott Williams &amp; Wilkins.</p></li><li data-list-text="4."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 85%;text-align: justify;">Steven How-Yan Wong, Irving Sunshine. Handbook of Analytical Therapeutic Drug Monitoring and Toxicology. CRC Press, USA.</p></li><li data-list-text="5."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 87%;text-align: justify;">Soraya Dhillon, Andrzej Kostrzewski. Clinical pharmacokinetics. 1st edition. London: Pharmaceutical Press.</p></li><li data-list-text="6."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 86%;text-align: justify;">Joseph T.Dipiro, William J.Spruill, William E.Wade, Robert A.Blouin and Jane M.Pruemer .Concepts in Clinical Pharmacokinetics. American Society of Health-System Pharmacists, USA.</p></li><li data-list-text="7."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 86%;text-align: justify;">Malcolm Rowland, Thomas N. Tozer .Clinical Pharmacokinetics and pharmacodynamics: concepts and applications. Iippincott Williams &amp; Wilkins, USA.</p></li><li data-list-text="8."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 85%;text-align: justify;">Evans, Schentag, Jusko. Applied pharmacokinetics. American Society of Health system Pharmacists, USA.</p></li><li data-list-text="9."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 86%;text-align: justify;">Michael E. Winter. Basic Clinical Pharmacokinetics. Iippincott Williams &amp; Wilkins, USA.</p></li><li data-list-text="10."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 87%;text-align: left;">Milo Gibaldi. Biopharmaceutics and Clinical Pharmacokinetics. Pharma Book Syndicate, USA.</p></li><li data-list-text="11."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 86%;text-align: left;">Dhillon and Kostrzewski. Clinical pharmacokinetics. Pharmaceutical Press, London.</p></li><li data-list-text="12."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 86%;text-align: left;">John E .Murphy. Clinical Pharmacokinetics. 5th edition. US: American Society of Health- System Pharmacist, USA.</p></li><li data-list-text="13."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 12pt;text-align: left;">Relevant review articles from recent medical and pharmaceutical literature</p></li></ol></li></ol><p class="s1" style="padding-top: 3pt;padding-left: 138pt;text-indent: -107pt;line-height: 112%;text-align: left;">PHARMACOEPIDEMIOLOGY &amp; PHARMACOECONOMICS (MPP 204T)</p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">Scope</p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 86%;text-align: justify;">This course enables students to understand various pharmacoepidemiological methods and their clinical applications. Also, it aims to impart knowledge on basic concepts, assumptions, terminology, and methods associated with Pharmacoeconomics and health related outcomes, and when should be appropriate Pharmacoeconomic model should be applied for a health care regimen.</p><p class="s2" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Objectives</p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Upon completion of this course it is expected that students shall be able to:</p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 12pt;text-align: left;">  <span class="p">Understand the various epidemiological methods and their applications</span></p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 13pt;text-align: left;">  <span class="p">Understand the fundamental principles of Pharmacoeconomics.</span></p><p class="s2" style="padding-top: 1pt;padding-left: 41pt;text-indent: -18pt;line-height: 86%;text-align: left;">  <span class="p">Identify and determine relevant cost and consequences associated with pharmacy products and services.</span></p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;">  <span class="p">Perform the key Pharmacoeconomics analysis methods</span></p><p class="s2" style="padding-top: 1pt;padding-left: 41pt;text-indent: -18pt;line-height: 86%;text-align: left;">  <span class="p">Understand the Pharmacoeconomic decision analysis methods and its applications.</span></p><p class="s2" style="padding-left: 23pt;text-indent: 0pt;line-height: 11pt;text-align: left;">  <span class="p">Describe current Pharmacoeconomic methods and issues.</span></p><p class="s2" style="padding-top: 1pt;padding-left: 41pt;text-indent: -18pt;line-height: 86%;text-align: left;">  <span class="p">Understand the applications of Pharmacoeconomics to various pharmacy settings.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">THEORY                                60 Hrs</p><p style="padding-top: 4pt;padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: left;">1.  <span class="s2">Introduction to Pharmacoepidemiology</span>: Definition, Scope, Need, Aims &amp; Applications; Outcome measurement: Outcome measures, Drug use measures: Monetary units, Number of prescriptions, units of drug dispensed, defined daily doses, prescribed daily doses, Diagnosis and Therapy surveys, Prevalence, Incidence rate, Monetary units, number of prescriptions, unit of drugs dispensed, defined daily doses and prescribed daily doses, medications adherence measurements. <span class="s2">Concept of risk: </span>Measurement of risk, Attributable risk and relative risk, Time- risk relationship and odds ratio</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ol id="l7"><li data-list-text="2"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">Pharmacoepidemiological Methods<span class="p">: Qualitative models: Drug Utilization Review; Quantitative models: case reports, case series, Cross sectional studies, Cohort and case control studies, Calculation of Odds’ ratio, Meta analysis models, Drug effects study in populations: Spontaneous reporting, Prescription event</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 8pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="padding-top: 2pt;padding-left: 27pt;text-indent: 0pt;line-height: 86%;text-align: left;">monitoring, Post marketing surveillance, Record linkage systems, Applications of Pharmacoepidemiology</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="3"><p class="s2" style="padding-top: 4pt;padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">Introduction  to  Pharmacoeconomics:  <span class="p">Definition, history of Pharmacoeconomics, Need of Pharmacoeconomic studies in Indian healthcare system.</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 90%;text-align: left;">Cost categorization and resources for  cost  estimation:  <span class="p">Direct costs. Indirect costs. Intangible costs.</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Outcomes and Measurements of Pharmacoeconomics: <span class="p">Types</span></p><p style="padding-left: 27pt;text-indent: 0pt;line-height: 86%;text-align: justify;">of outcomes: Clinical outcome, Economic outcomes, Humanistic outcomes; Quality Adjusted Life Years, Disability Adjusted Life Years Incremental Cost Effective Ratio, Average Cost Effective Ratio. Person Time, Willingness To Pay, Time Trade Off and Discounting.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="4"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 86%;text-align: justify;">Pharmacoeconomic evaluations: <span class="p">Definition, Steps involved, Applications, Advantages and disadvantages of the following Pharmacoeconomic models: Cost Minimization Analysis (CMA), Cost Benefit Analysis (CBA), Cost Effective Analysis (CEA), Cost Utility Analysis (CUA), Cost of Illness (COI), Cost Consequences Analysis (COA).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li data-list-text="5"><p class="s2" style="padding-left: 27pt;text-indent: -22pt;line-height: 79%;text-align: justify;">Definition, Steps involved, Applications, Advantages and disadvantages of the following:</p><p class="s2" style="padding-top: 4pt;padding-left: 27pt;text-indent: 0pt;line-height: 90%;text-align: justify;">Health related quality of life (HRQOL): <span class="p">Definition, Need for measurement of HRQOL, Common HRQOL measures.</span></p><p class="s2" style="padding-left: 27pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Definition, Steps involved, Applications of the  following:</p><p style="padding-top: 4pt;padding-left: 27pt;text-indent: 0pt;line-height: 85%;text-align: justify;">Decision Analysis and Decision tree, Sensitivity analysis, Markov Modeling, Software used in pharmacoeconomic analysis, Applications of Pharmacoeconomics.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">REFERENCES</p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">12</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Hrs</p><ol id="l8"><li data-list-text="1."><p style="padding-top: 6pt;padding-left: 26pt;text-indent: -13pt;line-height: 73%;text-align: justify;">Rascati K L. Essentials of Pharmacoeconomics, Woulters Kluwer Lippincott Williams &amp; Wilkins, Philadelphia.</p></li><li data-list-text="2."><p style="padding-left: 26pt;text-indent: -13pt;line-height: 87%;text-align: justify;">Thomas E Getzen. Health economics. Fundamentals and Flow of Funds. John Wiley &amp; Sons, USA.</p></li><li data-list-text="3."><p style="padding-left: 26pt;text-indent: -13pt;line-height: 86%;text-align: justify;">Andrew Briggs, Karl Claxton, Mark Sculpher. Decision Modelling for Health Economic Evaluation, Oxford University Press, London.</p></li><li data-list-text="4."><p style="padding-left: 26pt;text-indent: -13pt;line-height: 86%;text-align: justify;">Michael Drummond, Mark Sculpher, George Torrence, Bernie O&#39;Brien and Greg Stoddart. Methods for the Economic Evaluation of Health Care Programmes Oxford University Press, London.</p></li><li data-list-text="5."><p style="padding-top: 2pt;padding-left: 26pt;text-indent: -14pt;line-height: 86%;text-align: left;">George E  Mackinnon III. Understanding health outcomes and pharmacoeconomics.</p></li><li data-list-text="6."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 10pt;text-align: left;">Graker, Dennis. Pharmacoeconomics and outcomes.</p></li><li data-list-text="7."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 13pt;text-align: left;">Walley, Pharmacoeconomics.</p></li><li data-list-text="8."><p style="padding-top: 1pt;padding-left: 26pt;text-indent: -14pt;line-height: 86%;text-align: left;">Pharmacoeconomic – ed. by Nowakowska – University of Medical Sciences, Poznan.</p></li><li data-list-text="9."><p style="padding-left: 26pt;text-indent: -14pt;line-height: 12pt;text-align: left;">Relevant review articles from recent medical and pharmaceutical literature</p></li></ol></li></ol><p class="s1" style="padding-top: 3pt;padding-left: 141pt;text-indent: -65pt;line-height: 113%;text-align: left;">PHARMACY PRACTICE PRACTICAL - II (MPP 205P)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 86%;text-align: justify;">Pharmacy Practice practical component includes experiments covering important topics of the courses Principles of Quality Use of Medicines, Pharmacotherapeutics-II, Clinical Pharmacokinetics &amp; Therapeutic Drug Monitoring and Pharmacoepidemiology and Pharmacoeconomics.</p><p class="s2" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">List of Experiments (24)</p><ol id="l9"><li data-list-text="1."><p style="padding-top: 2pt;padding-left: 26pt;text-indent: -18pt;line-height: 13pt;text-align: left;">Causality assessment of adverse drug reactions (three)</p></li><li data-list-text="2."><p style="padding-left: 26pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Detection and management of medication errors (three)</p></li><li data-list-text="3."><p style="padding-left: 26pt;text-indent: -18pt;line-height: 12pt;text-align: left;">Rational use of medicines in special population (three)</p></li><li data-list-text="4."><p style="padding-top: 1pt;padding-left: 26pt;text-indent: -18pt;line-height: 85%;text-align: left;">Presentation of clinical cases of various disease conditions adopting Pharmaceutical Care Plan Model (eight)</p></li><li data-list-text="5."><p style="padding-left: 26pt;text-indent: -18pt;line-height: 11pt;text-align: left;">Calculation of Bioavailability and Bioequivalence from the given data (two)</p></li><li data-list-text="6."><p style="padding-top: 1pt;padding-left: 26pt;text-indent: -18pt;line-height: 85%;text-align: left;">Interpretation of Therapeutic Drug Monitoring reports of a given patient (three)</p></li><li data-list-text="7."><p style="padding-left: 26pt;text-indent: -18pt;line-height: 83%;text-align: left;">Calculation of various Pharmacoeconomic outcome analysis for the given data (two)</p></li></ol></body></html>
